Bio-Rad Laboratories BIO
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$6.99M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 38.8% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 4.97% to 4.33% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +215,747 | 0.8% |
| Morgan Stanley | Public Company | 2026/Q3 | +116,836 | 1.1% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +116,836 | 1.1% |
| Acadian Asset Management LLC | Mutual Fund | 2026/Q3 | +104,770 | 0.5% |
| Victory Capital Management Inc. | Mutual Fund | 2026/Q3 | +65,962 | 0.7% |
| Capital Research | Mutual Fund | 2026/Q3 | +49,604 | 3.6% |
| BlackRock | Mutual Fund | 2026/Q3 | +41,407 | 6.5% |
| Barclays PLC | Public Company | 2026/Q3 | +32,557 | 1.1% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +24,013 | 0.1% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +112,244 | 0.5% |
| Nomura Holdings, Inc. | Public Company | 2026/Q3 | +111,555 | 1.2% |
| Neuberger Berman Investment Advisers LLC | Mutual Fund | 2026/Q3 | +108,783 | 0.4% |
| SG Americas Securities, LLC | Private Company | 2026/Q3 | +103,817 | 0.6% |
| Victory Capital Management Inc. | Mutual Fund | 2026/Q3 | +103,487 | 0.5% |
| AQR Capital Management | Hedge Fund | 2026/Q3 | +98,209 | 0.7% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 9 Nov 2026 | Courtney Enloe | General Counsel | Open Market Disposition | -902 | $386.17 | 750 |
| 8 Nov 2026 | Jonathan DiVincenzo | President | Open Market Disposition | -919 | $390.47 | 1,962 |
| 8 Nov 2026 | James Barry | Executive VP & President of Life Science Group | Open Market Disposition | -1,400 | $385.63 | 625 |
| 23 Oct 2026 | Jonathan DiVincenzo | President | Derivative Exercise and Sale | -951 | $369.95 | 2,881 |
| 23 Oct 2026 | Jonathan DiVincenzo | President | Derivative Exercise and Retained | +918 | – | 2,881 |
| 19 Oct 2026 | Sedat Evran | Executive Vice President of Global Supply Chain | Derivative Exercise and Sale | -487 | $354.50 | 4,160 |
| 19 Oct 2026 | Sedat Evran | Executive Vice President of Global Supply Chain | Derivative Exercise and Retained | +557 | – | 4,160 |
| 5 Sep 2026 | Norman Schwartz | Chairperson & CEO | Derivative Exercise and Sale | -4,730 | $386.11 | 812,663 |
| 5 Sep 2026 | Norman Schwartz | Chairperson & CEO | Derivative Exercise and Retained | +2,834 | – | 812,663 |
| 5 Sep 2026 | Roop Lakkaraju | Chief Financial Officer | Derivative Exercise and Sale | -1,341 | $386.11 | 4,151 |
| 5 Sep 2026 | Roop Lakkaraju | Chief Financial Officer | Derivative Exercise and Retained | +1,565 | – | 4,151 |
| 5 Sep 2026 | Eva Engelhardt | Executive VP & President of the Clinical Diagnostics Group | Derivative Exercise and Sale | -854 | $386.11 | 1,828 |
| 5 Sep 2026 | Eva Engelhardt | Executive VP & President of the Clinical Diagnostics Group | Derivative Exercise and Retained | +1,325 | – | 1,828 |
| 5 Sep 2026 | Allison Schwartz | Director | Derivative Exercise and Sale | -116 | $386.11 | 1,734 |
| 5 Sep 2026 | Allison Schwartz | Director | Derivative Exercise and Retained | +204 | – | 1,734 |
| 5 Sep 2026 | James Barry | Executive VP & President of Life Science Group | Derivative Exercise and Sale | -839 | $386.11 | 2,025 |
| 5 Sep 2026 | James Barry | Executive VP & President of Life Science Group | Derivative Exercise and Retained | +1,244 | – | 2,025 |
| 5 Sep 2026 | Sedat Evran | Executive Vice President of Global Supply Chain | Derivative Exercise and Sale | -606 | $386.11 | 3,603 |
| 5 Sep 2026 | Sedat Evran | Executive Vice President of Global Supply Chain | Derivative Exercise and Retained | +1,285 | – | 3,603 |
| 5 Sep 2026 | Courtney Enloe | General Counsel | Derivative Exercise and Sale | -551 | $386.11 | 1,652 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 1,156,915 | 4.3% | 5.1 |
| 15 Oct 2026 | 1,097,562 | 4.1% | 4.8 |
| 30 Sep 2026 | 1,182,765 | 4.4% | 4.3 |
| 15 Sep 2026 | 998,654 | 3.7% | 3.8 |
| 31 Aug 2026 | 1,130,298 | 4.2% | 4.2 |
| 14 Aug 2026 | 1,327,739 | 5.0% | 4.8 |
No comments yet — be the first to weigh in on BIO.
Sign in to join the discussion.